Author of

• 25940

  +

  P2.03 - Biology (Not CME Accredited Session) (ID 952)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26942

    +

    P2.03-06 - Serum Syndechan-1 Levels in Patients with Nonsmall Cell Lung Cancer (ID 12088)

    16:45 - 18:00  |  Author(s): Meryem Iraz
    • Abstract
    • Slides

    Background
    

    Cytokines as polypeptide or glycopeptide molecules are the essential mediators of immune response and the inflammatory reactions in addition to numerous biological reaction they are involved in. Syndecans have an important role in a variety of cellular functions including cell proliferation and migration, and cell- /cell and cell-/matrix interactions. Syndechan-1 is a transmembrane heparan sulphate proteoglycans that is present on most cell types. In this study we aimed to evaluate the levels of syndecan-1, levels in non-small cell lung cancer (NSCLC), and to evaluate their relationship with tumor progression.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Sixtysix patients (F=3, M=63) with non-small cell lung cancer and 22 healthy (F=3, M=19) subject were enrolled this study. Patients with infections or other systemic disease were not included in the study. Serum levels of syndecan-1 was measured by ELISA system. Serum samples were obtained from each patient before the initiation of any type cancer treatment. They were centrifuged at 3000 rpm for 10min, and then stored at -70°C. Unpaired t-test was used to compare continuous variables between the patient group and control group and within the patient group according to TNM classification. Correlation analysis between cytokines and tumor stage was performed using the Pearson correlation coefficient. Sensitivity, specificity, positive predictive value and negative predictive values for syndecan-1 were determined using receiver operator characteristic analysis (ROC). These analyses were done to define clinically valid cutoff points to predict distant metastasis. A two-sided p values less than 0.05 was considered to be statistically significant.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Serum levels of syndecan-1 in patients with NSCLC were significantly higher than those of controls (p<0.001). In addition, mean levels of synde- can-1 in stage IV disease were significantly higher than non-metastatic NSCLC (p<0.001). In the patients with only one distant metastasis, levels of syndecan- 1 were found to be lower than those of the patients with multiple distant metastases. Syndecan-1 has high sensitivity (78%), specificity (91%), positive (88%) and negative predictive (80%) values for prediction of metastasis.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    In conclusion, we found that syndecan-1 changes significantly in serum of patients with NSCLC. In our study, these changes correlated well with the stage of lung cancer. Syndecan-1 with a high sensitivity, specificity and positive predictive value may be used in predicting the presence and nature (single or multiple) of metastasis. The authors believe that the current findings will provide clinicians with new insights, allowing them to implement more individualized treatment strategies in patients with lung cancer.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.